Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (309)
- Scheduling (national classification system) (165)
- Advertising (25)
- Safety monitoring and information (23)
- COVID-19 (11)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Clinical trials (4)
- Compliance and enforcement (4)
- Shortages and supply disruptions (3)
- Legislation (2)
- Breast implant hub (1)
- Cosmetics (1)
- Import and export (1)
- Manufacturing (1)
- Prescription opioids hub (1)
Search
580 result(s) found, displaying 51 to 75
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 4 April 2025
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 49 for meeting held 2 October 2024
-
Meeting statementsAdvisory Committee on Vaccines Statement 51 for meeting held 5 February 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 50 held 4 December 2024
-
Meeting statementsMeeting statement from the 15th Medical Devices Consumer Working Group (CWG) meeting that took place on 8 November 2024.
-
Scheduling decisions (interim)We have reopened the consultation on the interim decision regarding IV potassium in recognition of the broad impact of the proposed changes
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Corporate reportsThe findings will inform the need for any risk management actions to ensure public safety.
-
Scheduling decisions (final)Publication of the decisions made by a delegate of the Secretary in relation to to nicotinic acid.
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 1st meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 27 November 2024
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (interim)We are seeking submissions for a consultation on the interim decisions for IV potassium salts and nicotinic acid.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsRead our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
Meeting statementsAdvisory Committee on Medicines meeting statement